

Screening Libraries

Proteins

Inhibitors

Product Data Sheet

IFN-lambda 2/IL-28A Protein, Human (HEK293, His)

Cat. No.: HY-P72553

Synonyms: Interferon lambda-2; IFN-lambda-2; IL-28A; IFNL2; IL28A; ZCYTO20

Species: HEK293 Source:

Q8IZJ0 (V26-V200) Accession:

Gene ID: 282616

Molecular Weight: Approximately 20 kDa

PROPERTIES

| AA S | Sequ | ience |
|------|------|-------|
|------|------|-------|

VPVARLHGAL PDARGCHIAQ FKSLSPQELQ AFKRAKDALE ESLLLKDCRC HSRLFPRTWD LRQLQVRERP MALEAELALT LKVLEATADT DPALVDVLDQ PLHTLHHILS QFRACIQPQP TAGPRTRGRL PKKESPGCLE ASVTFNLFRL HHWLYRLQEA

LTRDLNCVAS GDLCV

Appearance

Lyophilized powder.

Formulation

Lyophilized from a 0.2 µm filtered solution of PBS, pH 7.4.

Endotoxin Level

<1 EU/µg, determined by LAL method.

Reconsititution

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Storage & Stability

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Shipping

Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background

IFN-lambda 2 (IL-28A) is a member of the Type-III interferon family. Human IFN-lambda 2 shares 65.1% common aa identity with mouse. IFN-lambda 2 is produced particularly by dendritic cells (DCs), When following viral or bacterial infection^[3]. IFN-lambda 2 mediates effects by a heterodimeric receptor complex comprising IFNλ receptor 1 (IFNLR1) and IL-10 receptor subunit-β (IL-10RB). When binding to the receptor complex, Jak1 and Tyk2 will be activated, and leads to subsequent tyrosine phosphorylation of the IFN-λR1 (intracellular domain, Tyr406 and Tyr343, Tyr517), and activation of STAT1 and STAT2. Activated STAT1 and STAT2 together with IRF-9 (p48) form a trimeric transcription factor complex (ISGF3). The formed ISGF3 complexes then translocate to the nucleus and promotes the production of IFN-stimulated genes (ISGs) such

as IRF7, MX1, and OAS1^[2].

IFN-lambda 2 has antiviral antitumour and immunomodulatory activities^[1]. IFN-lambda 2 has been reported to modulate CD11c+ DC cell function and promote Th1 differentiation, thus suppressing allergic airway diseases^[4].

REFERENCES

- [1]. Lopušná K, et al. Interferons lambda, new cytokines with antiviral activity. Acta Virol. 2013;57(2):171-9.
- [2]. Donnelly RP, et al. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res. 2010 Aug;30(8):555-64.
- [3]. Witte K, et al. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev. 2010 Aug;21(4):237-51.
- [4]. Yan B, et al. Interleukin-28B dampens airway inflammation through up-regulation of natural killer cell-derived IFN-y. Sci Rep. 2017 Jun 15;7(1):3556.
- [5]. Luo Q, et al. Interleukin 28 is a potential therapeutic target for sepsis. Clin Immunol. 2019 Aug;205:29-34.
- [6]. Liangzi Li, et al. Interleukin-28A maintains the intestinal epithelial barrier function through regulation of claudin-1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com